Patent ID: 6174903
Filing Date: 2001-01-16
Classification: A61K,C07D

Abstract:
A compound of the formula 1 ##STR11##or a pharmaceutically acceptable salt or solvate thereof, wherein:Z is --(CH.sub.2).sub.m -(imidazol-1-yl) wherein n is 1 or 2 or Z is a group of the formula ##STR12##R.sup.1 and R.sup.2 are each independently selected from the group consisting of H, C.sub.1 -C.sub.10 alkyl, --OR.sup.6, --C(O)(C.sub.1 -C.sub.10 alkyl), --(CH.sub.2).sub.t (C.sub.6 -C.sub.10 aryl), --(CH.sub.2).sub.t (5-10 membered heterocyclic), --C(O)(CH.sub.2).sub.t (C.sub.6 -C.sub.10 aryl), --(CH.sub.2).sub.t O(CH.sub.2).sub.j (C.sub.6 -C.sub.10 aryl), --C(O)(CH.sub.2).sub.t (5-10 membered heterocyclic), --SO.sub.2 (CH.sub.2).sub.t (C.sub.6 -C.sub.10 aryl), or --SO.sub.2 (CH.sub.2).sub.t (5-10 membered heterocyclic), wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 5, the --(CH.sub.2).sub.t -- moieties of the foregoing R.sup.1 and R.sup.2 groups optionally include a carbon-carbon double or triple bond where t is an integer between 2 and 5, and the foregoing R.sup.1 and R.sup.2 groups, other than H, are optionally substituted by 1 to 3 R.sup.5 substituents;R.sup.3 is --(CH.sub.2).sub.m (1- or 2-adamantyl), --(CH.sub.2).sub.m (C.sub.6 -C.sub.10 aryl), C.sub.1 -C.sub.15 alkyl, ##STR13##wherein m is an integer ranging from 0 to 6;X.sup.1, X.sup.2, and X.sup.3 are each independently C.sub.1 -C.sub.7 alkylene optionally containing 1 or 2 double or triple bonds where said alkylene contains at least two carbon atoms, X.sup.4 is a bond or C.sub.1 -C.sub.7 alkylene optionally containing 1 or 2 double or triple bonds where said alkylene contains at least two carbon atoms, and, in formula 3, the X.sup.4 moiety is attached to the X.sup.1 moiety at any available carbon in the X.sup.1 moiety's alkylene chain;R.sup.4 is C.sub.1 -C.sub.6 alkyl, --(CH.sub.2).sub.t (C.sub.6 -C.sub.10 aryl), or --(CH.sub.2).sub.t (5-10 membered heterocyclic), wherein said t is an integer ranging from 0 to 5 and said R.sup.4 groups are optionally substituted by 1 to 3 R.sup.5 substituents;each R.sup.5 is independently selected from the group consisting of halo, nitro, cyano, --C(O)OR.sup.5, --SO.sub.2 NR.sup.6 R.sup.8, --NR.sup.6 R.sup.8, --C(O)R.sup.6, --OR.sup.6, --C(O)NR.sup.6 R.sup.6 R.sup.8, --OC(O)NR.sup.6 R.sup.8, --NR.sup.8 C(O)NR.sup.8 R.sup.6, --NR.sup.8 C(O)R.sup.6, --NR.sup.8 C(O)O(C.sub.1 -C.sub.6 alkyl), --C(NR.sup.8)NR.sup.8 R.sup.6, --C(NCN)NR.sup.8 R.sup.6, --C(NCN)S(C.sub.1 -C.sub.6 alkyl), --NR.sup.8 C(NCN)S(C.sub.1 -C.sub.6 alkyl), --NR.sup.8 C(NCN)NR.sup.8 R.sup.6, --NR.sup.8 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --S(O).sub.n (C.sub.1 -C.sub.6 alkyl) wherein n is an integer ranging from 0 to 2,--NR.sup.8 C(O)C(O)NR.sup.8 R.sup.6, --NR.sup.8 C(O)C(O)R.sup.8, --SO.sub.2 (C.sub.6 -C.sub.10 aryl), --SO.sub.2 (5-10 membered heterocyclic), C.sub.6 -C.sub.10 aryl, 5-10 membered heterocyclic, and C.sub.1 -C.sub.4 alkyl optionally substituted by 1 to 3 fluoro substituents, wherein the aryl and heterocyclic moieties of said C.sub.6 -C.sub.10 aryl, 5-10 membered heterocyclic, --SO.sub.2 (C.sub.6 -C.sub.10 aryl) and --SO.sub.2 (5-10 membered heterocyclic) groups are optionally substituted by 1 or 2 groups independently selected from halo, nitro, cyano, --C(O)OR.sup.6, --SO.sub.2 NR.sup.6 R.sup.8, --NR.sup.6 R.sup.8, --C(O)R.sup.6, --OR.sup.6, and --S(O).sub.n (C.sub.1 -C.sub.6 alkyl) wherein n is 0 to 2;each R.sup.6 is independently hydrogen or C.sub.1 -C.sub.6 alkyl;each R.sup.7 is independently selected from cyano, --OR.sup.6,--OC(O)R.sup.6, --C(O)OR.sup.6, --C(O)NR.sup.6 R.sup.8, --NR.sup.6 R.sup.8, --SO.sub.2 NR.sup.6 R.sup.8, and C.sub.1 -C.sub.6 alkyl optionally substituted by hydroxy or up to three halo groups; and,each R.sup.8 is independently R.sup.6 or --OR.sup.6.